Abstract: Systems and methods to determine if an individual is impaired. The system includes a display and a stimulus on the display. The system includes a controller programmed to move the stimulus about the display and one or more sensors that track eye movements and pupil size of a user due to movement of the stimulus or light conditions. The system includes a processor programmed to analyze the eye movements and pupil data size. The system is programmed to determine the drug, or category of drug, causing impairment. The method includes using and collecting data from a testing apparatus. The method includes processing the data with an automated impairment decision engine to determine whether a subject is impaired. The method includes using machine learning models or statistical analysis to determine whether a test subject is impaired. The automated impairment decision engine may be trained using machine learning and/or statistical analysis.

Abstract: A mobile interface cart including a storage tank for receiving effluent from a dialysis (e.g., hemodialysis) procedure and a pump for pumping the effluent from the storage tank to an external waste drain located in the treatment center. In use, the pump enables the effluent to be moved over greater distances and/or around obstacles thereby eliminating, or at least minimizing, the need to construct expensive and time-consuming waste drains in the treatment center.

Abstract: Provided is disclosure for embodiments providing delivery of chemicals for conditioning a brush offline, where the brush is not coupled to a machine that makes use of the brush to clean a surface of an object.

Abstract: Technologies and implementations for a defibrillator electrode having communicative capabilities are generally disclosed.

Abstract: A brake booster assembly having a brake booster body and a pushrod as well as a pushrod-pedal coupler are provided. The pushrod travels along a pushrod axis when being pushed. The brake booster assembly includes a pushrod-pedal coupler. The pushrod-pedal coupler comprises a pushrod-attachment end arranged on the pushrod and defining a longitudinal axis parallel to the pushrod axis. A pedal-attachment end is configured to be attached to a pedal and having a pedal pivot axis around which the pedal pivots when being pushed. The pedal pivot axis extends across the longitudinal axis. A coupler hinge is arranged between the pushrod-attachment end and the pedal-attachment end and connects the pushrod-attachment end with the pedal-attachment end. The coupler hinge has a coupler hinge axis that extends across the longitudinal axis and the pedal pivot axis. The pedal pivot axis and the coupler hinge axis are offset along the longitudinal axis.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: An event data and location-linked spherical imaging system including a spherical imager configured for capturing a spherical image with an action; a localization device collocated with the spherical imager, the localization device configured for providing a location of the spherical imager; a level collocated with the spherical imager, the level configured for indicating an imaging level of the spherical imager; an event data receiver configured for receiving event data from a user, the event data is associated with one or more points of interest on the spherical image; and a compass configured for providing an orientation of the spherical imager in capturing the spherical image, wherein the orientation and location-linked event data is accessible within the context of the spherical image. In one embodiment, the spherical imager includes no more than two imagers. In one embodiment, the action is a single capture.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: The disclosure includes technology for analyzing financial instrument data and generating a forecast. An example method receives financial instrument data for a financial instrument; determines a financial dimension; parses the financial instrument data for occurrences of the financial dimension; computes historical price statistics for a set of time intervals relative to occurrences of the financial dimension; and generates pricing forecast relative to a point in time based on the historical price statistics.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: An event data and location-linked spherical imaging system including a spherical imager configured for capturing a spherical image with an action; a localization device collocated with the spherical imager, the localization device configured for providing a location of the spherical imager; a level collocated with the spherical imager, the level configured for indicating an imaging level of the spherical imager; an event data receiver configured for receiving event data from a user, the event data is associated with one or more points of interest on the spherical image; and a compass configured for providing an orientation of the spherical imager in capturing the spherical image, wherein the orientation and location-linked event data is accessible within the context of the spherical image. In one embodiment, the spherical imager includes no more than two imagers. In one embodiment, the action is a single capture.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: Disclosed are electronic gaming machines, methods and systems for gaming device configuration and gaming device software distribution. An electronic gaming machine is configured to detect whether a primary portable storage device is in communication with the electronic gaming machine. The primary portable storage device may be configured to store a boot image. The boot image may include a boot code, an operating system, and a framework application. The framework application may be configured to search and execute a pluggable module according to instructions provided by the pluggable module. The framework application may also include instructions configured to determine whether at least one of the one or more pluggable modules includes a signature and execute the at least one pluggable module when it is determined that the at least one pluggable module includes the signature.

Abstract: Disclosed are electronic gaming machines, methods and systems for gaming device configuration and gaming device software distribution. An electronic gaming machine is configured to detect whether a primary portable storage device is in communication with the electronic gaming machine. The primary portable storage device may be configured to store a boot image. The boot image may include a boot code, an operating system, and a framework application. The framework application may be configured to search and execute a pluggable module according to instructions provided by the pluggable module. The framework application may also include instructions configured to determine whether at least one of the one or more pluggable modules includes a signature and execute the at least one pluggable module when it is determined that the at least one pluggable module includes the signature.